Navigation Links
CoreLab Partners Launches New DXA Imaging Service Offerings

PRINCETON, N.J., Oct. 15 /PRNewswire/ -- CoreLab Partners, Inc, the global entity resulting from the merger between RadPharm Inc. and Medifacts International in February of this year, has launched a full suite of imaging service solutions and quality assurance processes as it relates to Dual Energy X-Ray Absorptiometry (DXA).

"We are pleased to announce that we have formally launched state-of-the-art imaging solutions to address the numerous indications and therapeutic areas of drug development requiring DXA imaging sciences," said CoreLab Partners' President and Chief Executive Officer, Dr. Mike Woehler. "The addition of DXA services to our growing list of modalities is a natural extension of our broad range of services as CoreLab Partners continues to expand its global reach and reputation for excellence across its cross-section of core lab services under our newly combined entity," added Woehler.  

This important launch correlates with the opening of the American Society of Bone Mineral Research (ASBMR) conference which will take place from October 15-19, 2010 at the Metro Toronto Convention Centre in Toronto, ON. Please visit CoreLab Partners at booth number #1507 to learn more about this exciting addition to their global suite of imaging sciences solutions and cardiac safety services.About CoreLab Partners, IncCoreLab Partners, with offices in North America, Europe and Asia, provides complete medical image assessment services to the pharmaceutical, biotechnology and medical device industries. An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with full-time, board certified, sub-specialty trained radiologists, cardiologists, nuclear medicine physicians and oncologists. CoreLab Partners also provides solutions for the collection, analysis and management of cardiac safety and efficacy information during drug development. Driven by best-in-class science, technology, and service quality, CoreLabs is a global leader providing ECG, TQT, Holter, Ambulatory Blood Pressure Monitoring, Spirometry, Glucometry, and Pulse Wave Analysis. Contact: Kevin D. DuffyVice President, Global Business DevelopmentEmail: kduffy@corelabpartners.comPhone: 609-936-2600This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE CoreLab Partners, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CoreLab Partners Completes First TQT Study in Japan
2. STALLERGENES : Significant Growth : Q3 2010 + 10% and +12% Over the First 9 Months / Shionogi Partnership: First EUR24 Million Instalment
3. UBC, Max Planck formalize partnership among worlds top quantum physicists
4. ReGear Life Sciences Partners with Life Care Centers of America
5. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
6. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
7. Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation
8. Pennsylvania Partnerships Address Statewide Nursing Shortage
9. DSM Biomedical Announces Continued Partnership with Spinelab
10. NanoPass Technologies Ltd. and Elcam Medical Enter Into a Strategic Partnership
11. Roche Diabetes Care and ICW Announce Technology Partnership
Post Your Comments:
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... ( ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... announced today it will be hosting a Webinar titled, “Pathology is going digital. ... Associates , on digital pathology adoption best practices and how Proscia improves lab ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):